Technology

Our Technology

Oxygen Microbubbles (OMBs) – Stabilized oxygen gas spheres delivered sterile to the physician. Every cell in the body requires oxygen to maintain correct homeostasis, and hypoxic conditions can quickly lead to irreversible organ damage or death. OMB technology has demonstrated the ability to deliver oxygen to the blood stream independent of the lungs. 

Research

Tight control of the size and composition allows for microbubbles to provide systemic oxygenation to patients with lung compromise. OMB are well characterized, stable, easy to transport, and inexpensive to produce. Phospholipids are the building blocks of cell membranes and are used to enhance drug safety. 

Initial Application: Acute Respiratory Distress Syndrome (ARDS)

ARDS is a rapidly progressing, severe lung disease commonly encountered in intensive care units (ICU) which makes breathing difficult or impossible. It can be caused by many different triggers, including sepsis, pneumonia, and trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe hypoxemia, which is refractory to oxygen treatment and requires assisted ventilation.

Why ARDS?

• There is no direct cure for ARDS 
• 40% mortality contributes to the death of 80,000 patients in the US every year, more than AIDS and breast cancer combined 
• Current treatment options are highly invasive and come with significant risk 

Respirogen OMB technology will provide systemic oxygen independent from the damaged lungs, reducing ventilator dependency and the need for Extracorporeal Membrane Oxygenation (ECMO).